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Abstract
Background: Despite today’s heightened concern over opioid overdose, the lack of population-based data
examining clinical and contextual factors associated with opioid use represents a knowledge gap with
relevance to prevention and treatment interventions. We sought to quantify rates of emergency department
(ED) visits and inpatient hospitalizations for harmful opioid effects and their sociodemographic differentials as well as
clinical correlates in Southern Nevada, using ED visit and hospital inpatient discharge records from 2011 to 2013.
Methods: Cases were identified by ICD-9-CM diagnosis codes for opioid poisoning and opioid-type drug dependence
and abuse as well as poisoning and adverse effect E-codes. Comorbid conditions, including pain-related diagnoses,
major chronic diseases, affective disorders, sleep disorders, sexually transmitted infections and viral hepatitis were
assessed from all available diagnosis fields. Counts by age-race per zip code were modeled by negative binomial
regression. Opioid injuries were further examined as a function both of neighborhood income and individual
characteristics, with mixed-effects logistic regression to estimate the likelihood for an adverse outcome.
Results: Opioid intoxications and comorbidities were more common in low-income communities. The multivariable-
adjusted rate for opioid-related healthcare utilization was 42 % higher in the poorest vs. richest quartile during
the study period. The inter-quartile (quartile 1 vs. 4) rate increases for chronic bodily pains (44 %), hypertension
(89 %), renal failure/diabetes (2.6 times), chronic lower respiratory disease (2.2 times), and affective disorders
(57 %) were statistically significant. Chronic disease comorbidity was greater among non-Hispanic blacks,
whereas abuse/dependence related disorders, alcohol or benzodiazepine co-use, chronic bodily pains, and
affective disorders were more prevalent among non-Hispanic whites than nonwhites.
Conclusions: There were consistent patterns of disparities in healthcare utilization across sociodemographic
groups for opioid-associated disorders. Further initiatives to evaluate the determinants of overdose and
abuse and to implement targeted response efforts are needed.
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Background
Drug-related poisonings have been recognized as a verit-
able epidemic in Clark County (coextensive with the Las
Vegas–Paradise Metropolitan Statistical Area [MSA]),
Southern Nevada, one of the most populous counties in
the United States (US). Since 2005, fatal drug poisonings
have surpassed firearm injuries as the leading cause of
injury deaths, and mortality from drug overdoses and
opioid poisonings in the county were 50 and 70 % higher
than comparable national rates in 2012–2014, respect-
ively [1]. Further, the excess mortality from drug-related
poisonings in Clark County has been linked to a higher
opioid prescribing rate in NV when compared with pre-
scribing patterns nationwide [2]. In view of these alarm-
ing statistics, the Nevada legislature enacted an opioid
overdose prevention policy in May, 2015, strengthen-
ing prescription drug monitoring programs use and
physician education programs, and expanding access
to naloxone, an opioid antagonist for reversing opioid
overdose in out-of-hospital settings.
Despite today’s heightened concern over opioid over-
dose, the lack of population-based data examining clin-
ical and contextual factors associated with opioid use
represents a knowledge gap with relevance to prevention
and treatment interventions. While risk factors and
trends for opioid-related fatalities have been reported in
limited populations [3, 4], fatal poisonings represent only
a small fraction of the potential adverse outcomes asso-
ciated with opioid use. Several studies have examined
the incidence and characteristics of hospitalizations and
emergency department (ED) visits for opioid overdose
[5–7]; however, epidemiologic data on correlates and co-
morbidities of opioid intoxication remain limited.
The purpose of this study is to examine medical en-
counters due to harmful opioid effects among major
sociodemographic subgroups in Southern Nevada, with
a focus on disorders comorbid with opioid use. Medical
encounter data can be used to improve our understand-
ing of the epidemiology of opioid overdose, and help de-
lineate groups at risk of adverse outcomes for targeted
interventions. Such interventions are urgently warranted




De-identified inpatient hospitalizations (IH) and ED visit
records of 2011–2013 were abstracted from the state-
wide inpatient and ED databases for Clark County resi-
dents. The inpatient and ED databases contain data for
approximately 200,000 IHs and 500,000 ED visits in
Clark County each year. Approximately 13 and 20 % of
the principal (first-listed) diagnoses for IHs and ED visits
are for some type of injury, with 87 and 91 % of these
injury-attributable inpatient or ED discharges having an
external cause of injury code (E-code), respectively.
Study endpoints
Hospitalizations and ED visits for opioid intoxication
were identified by ICD-9-CM diagnosis codes for opi-
oid overdose or poisoning (965.0) and opioid-type drug
dependence and abuse (304.0, 304.7, or 305.5) as well
as poisoning and adverse effect E-codes (E850.0-E850.2
[accidental poisoning by opioids and related narcotics],
E935.0-E935.2 [adverse effects of opioids and related
narcotics]). Opioid poisoning or abuse diagnoses primar-
ily reflect misuse (e.g., substance incorrectly administered
or given), non-medical use (e.g., without a prescription),
and conditions caused by abusive patterns of drug use
(e.g., dependence, psychoses), whereas opioid adverse
effects (e.g., delirium, tachycardia, vomiting) generally
indicate allergic or hypersensitivity reactions and ex-
clude unintentional (accidental) or suicidal overdoses
[8]. An opioid intoxication event therefore may involve
pharmaceutical (e.g., morphine, codeine, oxycodone,
hydrocodone, fentanyl, methadone, buprenorphine) or
nonpharmaceutical (e.g., heroin) substances. This case
definition enables a more complete representation of
opioid-related healthcare utilization, as pharmaceutical
opioid consumption and heroin use are increasingly
overlapping problems [9, 10]. Opioid-related medical
encounters were also examined for alcohol, benzodi-
azepine (BZD) and non-opioid illicit drug (e.g., cocaine,
cannabinoids, hallucinogens and other psychostimu-
lants) involvement, given their well-documented contri-
butions to poisoning fatalities [11–15]. Comorbid
conditions, including pain-related diagnoses, major
chronic diseases (hypertension, ischaemic heart disease,
renal failure/diabetes, cancer, chronic lower respiratory
disease [CLRD]), affective disorders, sleep disorders,
sexually transmitted infections (STI) and viral hepatitis
were assessed from all available diagnosis fields. Addition-
ally, accidental and self-harm or suicidal intents were
determined using injury-related E-codes if recorded
(E850-E858 [accidental poisoning by drugs] and
E950.0-E950.5 [self-inflicted poisoning by drugs]). All
other cases, including opioid poisoning or abuse re-
lated injuries of other and uncoded intents and ex-
cluding opioid adverse effects, were combined into an
‘other opioid misuses’ category in intent-specific analyses.
Statistical analysis
To determine how opioid intoxications varied across so-
cioeconomic settings, aggregated age and race-specific
opioid cases were linked to population characteristics
from the US Census five-year (2009–2013) American
Community Survey by residential zip code to incorpor-
ate median household income and denominator data. To
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the extent that features of the social environment such
as neighborhood income and place of residence influ-
ence health outcomes, health services utilization, and
the context of drug availability, counts (by age and race)
of opioid-related medical encounters within the same
zip code may be more similar than those in different zip
codes (i.e., counts may be autocorrelated). As such, they
were modeled by negative binomial regression with the
generalized estimating equations (GEE) to allow for
autocorrelation and potential overdispersion (i.e., vari-
ance is greater than mean) [16]. The GEE estimation
assumed an unstructured working correlation for
counts over clusters (i.e., zip codes), and controlled for
differences in age, race (restricted to non-Hispanic
white, black and Hispanic patients) and male-to-female
ratio (per patient’s zip code) as well as unobserved con-
textual heterogeneities (of the 74 zip codes from the data
linkage) in calculating the rate for opioid intoxication and
comorbidities by areal-level income. Variations in rates
across income quartiles were expressed as multivariable-
adjusted rate ratios (using the 4th income quartile as the
reference group). The GENMOD procedure of SAS 9.3
(Cary, NC, USA) was used to perform the analysis.
Opioid injury and comorbidities were further exam-
ined as a function both of neighborhood income and in-
dividual characteristics (age, gender, race, insurance
type), with mixed-effects logistic regression to estimate
the likelihood for an adverse outcome. Per standard
mixed-effects modeling, a random intercept deviation
(for each zip code) was adopted to account for the ef-
fects of socio-spatial context, that is, interdependencies
of opioid-related medical encounters within each zip
code. Accidental poisonings were compared with other
opioid misuse cases (including suicidal poisonings), sui-
cidal poisonings with other opioid misuse cases (includ-
ing accidental poisonings), and comorbidity-involved
cases with those without the concomitant condition, re-
spectively, to derive multivariable-adjusted odds ratio
(AOR) estimates for selected study endpoints across
major racial groups (using non-Hispanic white [NHW]
as the reference group). The GLIMMIX procedure of
SAS 9.3 was used for the mixed-effects analysis.
Results
For the 3-year study period (2011–2013), there were a
total of 4,631 ED visits and 5,016 IHs among residents
in Southern Nevada which were attributable to the use
of opioids. These ED visits and IHs constituted about
a quarter of drug-induced emergency visits and one-
half of drug-induced hospitalizations, respectively.
The overall rate of opioid-related intoxications was
161.0 per 100,000, with ED visit rates peaking in ages
20–34 (147.7 per 100,000) and IH rates in ages 55 and
above (127.8 per 100,000). More than half of opioid
intoxication cases were among women, and close to
three-quarters among those of non-Hispanic white
origin (Table 1). The most common type of insurance
among inpatients was private coverage (37.4 %),
followed by Medicare (33.1 %) and Medicaid (12.9 %),
while self-pay was most common for ED visits
(34.3 %), followed by private coverage (28.4 %) and
Medicare (14.9 %). More Hispanic patients were
treated in ED than in hospitals, and self-pay (as the
primary payer) was more likely among Hispanics than
other races. Hospitalizations lasted 5–6 days on aver-
age, and discharge to home or self-care occurred in al-
most two-thirds of the patients. Median charges per
patient in 2013 were $4,528 (interquartile range:
$2,334 to $7,126) in ED visits without hospitalization
and $24,659 ($10,604 to $59,622) in IHs. Diagnosis of opi-
oid poisoning or adverse effects was associated with sub-
stantial increases in hospital care costs, with median IH
charges of $41,329 and $62,757 respectively.
Of the 9,647 opioid use or misuse related medical en-
counters in 2011–2013, 23.9 % (2,305) were coded as
unintentional injury and 9.6 % (930) suicidal, whereas
adverse effects were the first-listed diagnosis in about
17 % (1,663) of cases. (Of the opioid poisoning cases
assigned an injury-related E-code [3,547], 65 % were
classified as accidental and 26.2 % suicidal.) Females
aged 55 years and above comprised almost 40 % (639) of
all opioid adverse effect cases, versus 16.6 % (589) of
opioid poisoning cases. Fatalities (49 inpatient and 4 ED
cases at time of discharge) occurred predominantly
among inpatients (at a rate of 1 %), to those aged 55 and
above, and were most frequently related to accidental
exposure to opioid drugs (22 accidental vs. 13 suicidal
poisonings). In comparison to patients hospitalized for
non-opioid related drug intoxications, opioid cases were
more likely to be women, aged 55 years and above, to
have private coverage or Medicare as the primary payer,
to have longer hospital stays, and to be transferred to
another facility or self-care.
As well, females made up a larger proportion of sui-
cidal (60.9 %) than accidental poisonings (50.4 %), and
ages 35–54 the largest proportion of suicidal poisonings
(38.8 %), whereas ages 55 and above the largest propor-
tion of accidental poisonings (36 %). Compared with
opioid overdose deaths identified from vital records
(data not shown), opioid-related medical encounters
had lower involvement of alcohol (7.2 %), BZD (8.5 %),
or illicit/recreational drugs (11.6 %) (diagnoses for sub-
stances involved are not mutually exclusive). Nonethe-
less, rates of alcohol (15.7 %) or BZD (29.5 %)
involvement were higher in suicidal than accidental
poisonings (8.5 % and 18.3 % respectively). Alcohol
co-use among opioid cases was most commonly found
in males aged 35–54, BZD co-use in similarly-aged
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females, and illicit drug co-use in males under 35 years
of age (Table 1).
The most frequent comorbidities among opioid-
related ED or hospital visits were chronic bodily/muscu-
loskeletal pains and affective disorders (e.g., depression,
bipolar disorders, depressive/affective psychoses), listed
as comorbid diagnoses in 30.6 and 26.8 % of the exam-
ined opioid cases respectively (comorbid conditions are
not mutually exclusive) (Table 1). Chronic bodily pains
were more pronounced among IHs (44.9 %) than ED
visits (15 %), and affective disorders (19.1 %) more not-
able than chronic bodily pains among ED visits. Other
conditions commonly found among opioid cases were
hypertension (24.6 %), renal failure/diabetes (14.2 %),
CLRD (11.9 %), ischaemic heart disease (6 %), sleep dis-
orders (4.1 %), and STI/viral hepatitis (3.5 %). ED service
and IH costs increased substantially with a major
chronic disease (hypertension, ischaemic heart disease,
Table 1 Opioids-Attributable ED Visits and Inpatient Hospitalizations (IH) by Selected Characteristics, Clark County-NV, 2011-2013
ED visit IH Total Encounters Alcohol-related BZD-related Illicit/recreational
drug-relatedc
No. %a No. %a No. %a Rateb No. %a Rateb No. %a Rateb No. %a Rateb
Total 4,631 100.0 5,016 100.0 9,647 100.0 161.0 697 100.0 11.6 817 100.0 13.6 1,120 100.0 18.7
Age
< 20 y 408 8.8 283 5.6 691 7.2 43.1 24 3.4 1.5 39 4.8 2.4 122 10.9 7.6
20–34 1,911 41.3 1,450 28.9 3,361 34.8 259.7 204 29.3 15.8 245 30.0 18.9 550 49.1 42.5
35–54 1,478 31.9 1,469 29.3 2,947 30.5 176.1 305 43.8 18.2 320 39.2 19.1 331 29.6 19.8
55+ 834 18.0 1,814 36.2 2,648 27.4 186.6 164 23.5 11.6 213 26.1 15.0 117 10.4 8.2
Gender
Female 2,341 50.6 2,674 53.3 5,015 52.0 168.2 273 39.2 9.2 450 55.1 15.1 483 43.1 16.2
Male 2,290 49.4 2,342 46.7 4,632 48.0 153.9 424 60.8 14.1 367 44.9 12.2 637 56.9 21.2
Race
Non-Hispanic white 3,342 72.2 3,787 75.5 7,129 73.9 247.1 534 76.6 18.5 616 75.4 21.3 805 71.9 27.9
Non-Hispanic black 455 9.8 458 9.1 913 9.5 135.7 53 7.6 7.9 68 8.3 10.1 119 10.6 17.7
Hispanic 535 11.6 369 7.4 904 9.4 50.7 62 8.9 3.5 78 9.5 4.4 105 9.4 5.9
Other 299 6.5 402 8.0 701 7.3 107.5 48 6.9 7.4 55 6.7 8.4 91 8.1 14.0
Insurance type
Medicaid 563 12.2 645 12.9 1,208 12.5 – 88 12.6 – 138 16.9 – 168 15.0 –
Medicare 689 14.9 1,661 33.1 2,350 24.4 – 128 18.4 – 190 23.3 – 130 11.6 –
Other public (military, indigent,
charity)
336 7.3 366 7.3 702 7.3 – 92 13.2 – 68 8.3 – 159 14.2 –
Private (including workers’ comp) 1,314 28.4 1,878 37.4 3,192 33.1 – 205 29.4 – 222 27.2 – 307 27.4 –
Self-pay 1,590 34.3 413 8.2 2,003 20.8 – 171 24.5 – 185 22.6 – 319 28.5 –
Other/unknown 139 3.0 53 1.1 192 2.0 – 13 1.9 – 14 1.7 – 37 3.3 –
Selected comorbiditiesa
Chronic bodily pains 696 15.0 2,253 44.9 2,949 30.6 49.2 190 27.3 3.2 295 36.1 4.9 226 20.2 3.8
Affective disorders 885 19.1 1,698 33.9 2,583 26.8 43.1 272 39.0 4.5 425 52.0 7.1 340 30.4 5.7
Hypertension 565 12.2 1,811 36.1 2,376 24.6 39.7 158 22.7 2.6 215 26.3 3.6 158 14.1 2.6
Renal failure/diabetes 244 5.3 1,130 22.5 1,374 14.2 22.9 90 12.9 1.5 149 18.2 2.5 105 9.4 1.8
Chronic lower respiratory disease 255 5.5 892 17.8 1,147 11.9 19.1 83 11.9 1.4 100 12.2 1.7 113 10.1 1.9
Ischemic heart disease 90 1.9 493 9.8 583 6.0 9.7 30 4.3 0.5 55 6.7 0.9 44 3.9 0.7
Sleep disorders 57 1.2 341 6.8 398 4.1 6.6 26 3.7 0.4 37 4.5 0.6 34 3.0 0.6
STI/viral hepatitis 68 1.5 265 5.3 333 3.5 5.6 56 8.0 0.9 38 4.7 0.6 64 5.7 1.1
aComorbid conditions are not mutually exclusive. Crude rates are based on Census total population estimates (average 2011–2013)
bRates are per 100,000 Census population estimates by demographic subgroups unless specified otherwise
cIllicit/recreational drugs include cocaine, cannabinoids, hallucinogens and other stimulants with abuse potential
–Not estimated
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renal failure/diabetes, cancer, CLRD) comorbidity (from
$4,299 and $14,659 to $6,284 and $43,686 in median ED
and IH charges in 2013, respectively).
Of the 3,923 opioid-related medical encounters with a
pain co-diagnosis, 75.2 % (2,949) were associated with
chronic bodily pains, 16.1 % (633) with a psychological
disorder or psychogenic pain, 13.1 % (513) with a non-
poisoning injury or acute pain, 8.5 % (334) with neur-
opathy, 7.4 % (292) with headache, and 5.6 % (219) with
cancer (pain-related diagnoses are not mutually exclu-
sive). Whereas 41 % of all opioid cases had one or more
pain-caused conditions, the proportion rose to 64 %
(1,068) among cases diagnosed as adverse effects. As
well, pain care was bound up with the management of
other physical ailments, given the high co-occurrence of
pain (2,244 or 65 %) among those with a major chronic
disease diagnosis (3,453).
Opioid intoxications were more common in low-
income communities (Fig. 1; zip code used as the enu-
meration area), and this socioeconomic disparity per-
sisted after accounting for the effects of age, gender and
race. Figure 2 shows the multivariable-adjusted rate ra-
tios for opioid intoxication and selected comorbid diag-
noses, comparing zip codes grouped into lower income
quartiles (on the basis of median household income) to
the richest quartile (quartile 4). There was a general pat-
tern of increase in opioid intoxications and examined
comorbidities for individuals living in low-income areas.
The multivariable-adjusted rate for opioid-related
healthcare utilization was 42 % higher in the poorest
(median income $33,029) vs. richest ($76,030) quartile
during the study period, whereas for opioid cases coded
as either accidental or suicidal poisoning, related med-
ical encounters showed greater inter-quartile disparities,
with rates about twice as high in the poorest vs. richest
quartile. Marked socioeconomic differentials were also
apparent in the prevalence of chronic bodily pains,
chronic diseases (except for cancer), and affective disor-
ders among opioid cases, with residents of poorer quar-
tiles at much higher risk. The inter-quartile (quartile 1
vs. 4) rate increases for comorbidities such as chronic
bodily pains (44 %), hypertension (89 %), renal failure/
diabetes (2.6 times), CLRD (2.2 times), and affective dis-
orders (57 %) were all statistically significant. Similarly,
poorer neighborhoods retained significantly higher rates
for non-opioid substance co-use: the poorest quartile
had about 3 times the rate for alcohol or illicit drug co-
use, and twice that for BZD co-use compared with the
richest quartile.
In addition, opioid morbidity and comorbidity patterns
varied by race after adjustment for age, gender, insurance
type, and neighborhood income (Fig. 3). Among opioid
cases treated in ED or hospital and relative to NHWs,
the multivariable-adjusted odds of accidental opioid
Fig. 1 Rate of Opioid-Involved Medical Encounters by Residential Zip Code, Southern Nevada Metro Enlargement, 2011-2013
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poisoning (vs. other opioid misuse related intoxications)
were 22 % higher for non-Hispanic blacks (NHB), and
61 % higher for Hispanics. Similar disparities were seen
for suicidal opioid poisoning (vs. other opioid misuse re-
lated intoxications), with the odds 56 % higher among
Hispanics and elevated albeit nonsignificantly among
NHBs. Also, NHBs and Hispanics had substantially in-
creased odds of opioid adverse effects (vs. opioid misuse
related intoxications), which were twice the odds for
NHWs. Further, chronic disease comorbidity was greater
among NHBs, due in large part to greater odds of co-
occurring hypertension (AOR of 2.01) and renal failure/
diabetes (1.59) in NHBs. As well, Hispanics had signifi-
cantly greater odds for concomitant renal failure/diabetes
(1.57), albeit comparatively lower odds for other
chronic disease comorbidities than NHWs. On the
other hand, opioid drug abuse or dependence related
disorders, alcohol or BZD co-use, and correlates of
opioid intoxication such as chronic bodily pains,
affective disorders and sleep disorders were more
prevalent among NHWs than nonwhites.
Discussion
Using de-identified ED and hospital discharge records,
we evaluated health service utilization associated with
opioid intoxication and its relationship with sociodemo-
graphic and clinical factors in a large metropolitan area
(the Las Vegas–Paradise MSA). We observed substantial
opioid morbidity burden, as measured by both health-
care utilization and expenditure. Opioid use and misuse
were implicated in over 1,500 emergency visits and
1,700 IHs annually during the study period, and
opioid-related intoxications cost Southern Nevada’s
health system about $9.3 million in ED service costs
and $92.5 million in inpatient healthcare costs in 2013.
Important opioid comorbidities include pain, affective
disorders, and chronic physical ailments, with a high
co-occurrence of pain among patients affected by a
major chronic condition. These findings suggest that
enhanced overdose screening (e.g., urine toxicology, as-
certainment of substance use history), especially of
patients being treated for pain, is warranted as a key
component of prevention-oriented care.
Fig. 2 Income Inter-Quartile Rate Ratios with 95 % Confidence Limits for Opioid-Involved Medical Encounters, Clark County-Nevada, 2011-2013
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Indeed, pain management is a significant area of
healthcare expenditure, amounting to two-thirds ($67
million) of the total ED and IH charges in Southern
Nevada for opioid-related intoxications in 2013. Further,
the significance of pain and coexistent emotional or
physical problems extend beyond opioid overdose or ad-
diction and related healthcare costs. It was estimated
that pain-attributable medical care contributed about
47 % of the annual economic costs of pain in the United
States, while pain-induced workplace costs (e.g., lost
productivity) made up the rest of the related economic
burden [17]. Importantly, cost estimates are necessarily
conservative as the effects of pain on social functioning,
emotional well-being and quality of life are difficult if
not impossible to monetize. As such, there are compel-
ling economic and moral imperatives to make pain pre-
vention a public health priority [18].
The current analyses indicate that there are leverage
points for the mitigation of pain and opioid-related
healthcare costs. Most notably, opioid-related disorders
are highly comorbid, and low-income neighborhoods ex-
perience a disproportionate burden of opioid intoxica-
tions and comorbidites ranging from prevalent chronic
diseases to affective disorders. As low-income patients
were more likely to use acute hospital care and less
likely to access primary care or obtain specialty referral
than middle- and high-income patients [19–22], a case
could therefore be made for improving the capacity of
and access to evidence-informed pain care and behav-
ioral health services in primary care settings on the
grounds of the possible improvements in health system
efficiency that could result. This includes developing
comprehensive screening and assessment tools to en-
hance the critical detection and referral roles of primary
care services, implementing quality assurance standards
to encourage multi-disciplinary pain management ap-
proaches (e.g., medical and psychosocial interventions),
aligning insurance incentives with standards of care,
building the competencies of the substance abuse and
mental health workforce, and focusing prevention and
outreach services on low-income populations.
Results from this study indicate that NHWs had
greater opioid-related health service utilization than
nonwhites. In light of previous evidence on similar racial
disparities [23–25], this pattern may suggest that non-
white individuals did not experience the pain reduction
benefits or associated risks of opioid medications to the
same degree as NHWs. This racial disparity may relate
to sociocultural differences in pain perception and
reporting, patient-provider interactions, potential bar-
riers to analgesic treatment, and differential opioid-
taking behavior [23, 26–29]. As such, future work to
explore patient (e.g., treatment preferences, presenta-
tion, copying strategies) and provider (e.g., treatment
Fig. 3 Odds Ratios with 95 % Confidence Limits for Opioid-Involved Medical Encounters across Select Racial Groups, Clark County-Nevada, 2011-2013
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modalities, prescribing patterns) related factors as well
as information derived from patient-provider interac-
tions could contribute to a better understanding of the
racial disparities in healthcare utilization. As well, add-
itional studies on the nature and extent of pain dispar-
ities in diverse populations could help clarify when
higher medical encounter rates are the result of avoid-
able health service utilization and when they reflect a
greater need for pain treatment and management.
While administrative data are unable to address pain
disparities or clinical practice variations in pain care, the
higher rates of opioid abuse or dependence related disor-
ders and additional psychotherapeutics (e.g., BZD) use
among NHWs emphasize the need for vigilance about
possible progression from legitimate medical use to sub-
stance abuse and dependence in this population. The
finding of elevated odds for affective disorders among
NHWs compared with nonwhites also deserves mention,
and supports previous reports of higher psychiatric co-
morbidity in vulnerable populations [3, 5, 30, 31].
Clearly, the association of chronic pain and psychiatric
disorders, with their underlying risk and protective
factors, should be a focus in etiologic and prevention
research. On the other hand, the relative risks for opi-
oid poisoning (vs. abuse or dependence) and opioid
adverse effects (vs. poisoning and abuse/dependence)
were significantly higher among NHBs and Hispanics
than among NHWs, suggesting a need for targeted
overdose education, suicide screening, and close monitor-
ing of complications among minority patients. Further,
opioid poisoning and adverse effects were associated with
higher healthcare costs and poorer clinical status, as
reflected in their higher-weighted case-mix evaluations
(data not shown) when compared with abuse or depend-
ence diagnoses. This suggests that broader prevention
initiatives—such as preventive care and early disease
management—may go some way towards mitigating the
risks of opioid comorbidities and related healthcare costs.
The current study expands the scope of existing litera-
ture on opioid-related morbidity by incorporating the
spectrum of opioid injury comprising poisoning, abuse
or dependence, and adverse effects. Most prior studies
have focused on fatal/nonfatal overdoses (exclusive of
adverse effects) or non-medical use. Therefore, very little
information is available on potential factors associated
with both opioid misuse and adverse effect events. We
characterized medical and non-medical opioid users’
patterns of healthcare utilization by estimating their as-
sociation with sociodemographic and clinical risk factors
in large-scale, population-based samples. Our findings
further describe the relationship of opioid intoxication
risk to socioeconomic status and the differential clinical
characteristics (such as comorbid diagnoses) among
demographic subgroups. We noted elevated risk for
opioid overdose and adverse effects among nonwhite
populations, and among NHW populations, increased
risk for opioid abuse and psychiatric problems. These
data underscore the importance of a multifaceted pre-
vention approach that encompasses both mental health
strategies and clinical interventions (such as heightened
surveillance of at-risk patients who may benefit from
other treatment modalities).
There are a number of limitations to this study. First,
its cross-sectional nature precludes the demonstration
of a cause-and-effect relationship between healthcare
utilization and individual or ecologic covariates. Sec-
ond, lack of adjustment for potential confounders
including individual (e.g., disability, medical history, life-
style behaviors) and socioeconomic (e.g., employment,
education, neighborhood resources) correlates could have
resulted in overestimating the magnitude of intoxication
risks due to measured covariates. In addition, the use of
ecologic covariate such as zip code level male-to-female
ratio in income-attributable effect estimation may have
inadequately adjusted for the possibility of confounding
by gender. Third, the ICD-9-CM diagnosis codes for
opioid-type drug abuse/dependence do not differentiate
between prescription and illicit (e.g., heroin) opioid-
involved disorders. Accordingly, underestimation of
illicit drug-related intoxications likely led to a conserva-
tive bias with fewer differences observed between sociode-
mographic groups. Fourth, we were unable to account for
repeat medical encounters as deidentified data sources
preclude follow-up of patients over time. Last, data avail-
able for this study do not permit in-depth examination of
factors contributing to the opioid overdose risk that oc-
curred disproportionally more often among residents in
Southern Nevada than in the rest of the nation. Future
work to understand the geographic patterns of opioid in-
toxication could therefore facilitate identification of eco-
nomic and socio-environmental exposure pathways that
would inform operationally specific policy interven-
tions. Whereas our findings reinforce income-mediated
behavioral and mental health disparities, other research
has indicated that higher levels of social spending for
low-income residents significantly reduced health and
life expectancy disparities along the income gradients
[32]. Thus, it is possible that resource commitment to
the mitigation of income inequality and social disinvest-
ment is a policy lever with importance to overdose
prevention.
Conclusions
This study extends previous research by evaluating
health service utilization associated with opioid intoxica-
tion and its relationship with sociodemographic and
clinical factors in an urban setting. There were consist-
ent patterns of disparities in healthcare utilization across
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sociodemographic groups for opioid-associated disor-
ders, with low-income neighborhoods experiencing a
disproportionate burden. Further initiatives to evaluate
the determinants of overdose and abuse and to imple-
ment targeted response efforts are needed. At the popu-
lation and health system level, intervention strategies
informed by the etiology of pain including its physical
and psychosocial correlates would prove beneficial in re-
ducing opioid-associated healthcare utilization.
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